GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Cyclically Adjusted FCF per Share

StageZero Life Sciences (TSX:SZLS) Cyclically Adjusted FCF per Share : C$-0.32 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

StageZero Life Sciences's adjusted free cash flow per share for the three months ended in Mar. 2024 was C$-0.001. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is C$-0.32 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 21.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 25.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of StageZero Life Sciences was 33.10% per year. The lowest was 4.20% per year. And the median was 18.20% per year.

As of today (2024-09-20), StageZero Life Sciences's current stock price is C$0.04. StageZero Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was C$-0.32. StageZero Life Sciences's Cyclically Adjusted Price-to-FCF of today is .


StageZero Life Sciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for StageZero Life Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Cyclically Adjusted FCF per Share Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.33 -0.90 -0.74 -0.61 -0.43

StageZero Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 -0.40 - -0.35 -0.32

Competitive Comparison of StageZero Life Sciences's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, StageZero Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



StageZero Life Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, StageZero Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.001/126.2576*126.2576
=-0.001

Current CPI (Mar. 2024) = 126.2576.

StageZero Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.192 98.604 -0.246
201406 -0.131 99.473 -0.166
201409 0.030 99.394 0.038
201412 -0.029 98.367 -0.037
201503 0.043 99.789 0.054
201506 -0.226 100.500 -0.284
201509 -0.145 100.421 -0.182
201512 -0.063 99.947 -0.080
201603 -0.055 101.054 -0.069
201606 -0.106 102.002 -0.131
201609 -0.197 101.765 -0.244
201612 -0.185 101.449 -0.230
201703 -0.181 102.634 -0.223
201706 -0.129 103.029 -0.158
201709 -0.072 103.345 -0.088
201712 -0.040 103.345 -0.049
201803 -0.082 105.004 -0.099
201806 -0.089 105.557 -0.106
201809 -0.056 105.636 -0.067
201812 -0.045 105.399 -0.054
201903 -0.081 106.979 -0.096
201906 -0.022 107.690 -0.026
201909 -0.174 107.611 -0.204
201912 -0.008 107.769 -0.009
202003 -0.050 107.927 -0.058
202006 -0.014 108.401 -0.016
202009 -0.036 108.164 -0.042
202012 -0.002 108.559 -0.002
202103 -0.021 110.298 -0.024
202106 -0.048 111.720 -0.054
202109 -0.041 112.905 -0.046
202112 -0.040 113.774 -0.044
202203 -0.028 117.646 -0.030
202206 -0.006 120.806 -0.006
202209 -0.001 120.648 -0.001
202212 -0.009 120.964 -0.009
202303 -0.003 122.702 -0.003
202306 0.000 124.203 0.000
202309 0.001 125.230 0.001
202403 -0.001 126.258 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


StageZero Life Sciences  (TSX:SZLS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


StageZero Life Sciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Executives
James Howard-tripp Director, Senior Officer

StageZero Life Sciences Headlines

No Headlines